Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Solly Chedid, MD
Articles by Solly Chedid, MD
Panel Discusses Imetelstat for Lower-Risk MDS Treatment
Melissa Badamo
Myelodysplastic Syndromes
|
November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
View More
Which Patients Should Be Treated With Luspatercept?
Melissa Badamo
Myelodysplastic Syndromes
|
November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
View More
Panel Describes Dosing Considerations for Luspatercept in Lower-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
View More
Panel Discusses COMMANDS Data in Lower-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
View More
How Do Prognostic Models Factor into Treatment Decision Making for MDS?
Melissa Badamo
Myelodysplastic Syndromes
|
November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
View More
How Is the MDS Patient Experience Measured?
Melissa Badamo
Myelodysplastic Syndromes
|
November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
View More
What Is the Current MDS Treatment Landscape?
Guillermo Garcia-Manero, MD
Myelodysplastic Syndromes
|
November 6, 2024
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
View More
Dr. Chedid on Phase III COMMANDS Findings in MDS, Anemia
Solly Chedid, MD
Myelodysplastic Syndromes
|
October 24, 2024
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
View More